eli lilly retatrutide trial sign up Retatrutide, an experimental weight-loss drug, has not been approved retatrutide safety clinical trials A

New in FY2027 GLP-1 Medication Coverage for the Treatment of Obesity Coverage for GLP-1 medications prescribed for the treatment of obesity only, under GIC health plans, will end at the end of Fiscal Year 2026 (FY3036), June 30, 2026 for non-Medicare plan members and on December 31, 2026 for Medicare plan members

Your body needs its minerals, too

GLP-1 and the brains powerhouse: a new perspective on the role of mitochondria in neuroprotection

But even here, a subset of patients will fail either mono or combination therapy with low cost generics, and they will need to be stepped up to more potent agents such as semaglutide, Wegovy, or tirzepatide, Zepbound

How compounded GLP-1 medications keep costs low Compounded medications from licensed 503A pharmacies cost significantly less than brand-name alternatives because they bypass manufacturer markups and direct-to-consumer advertising expenses

For a research context, retatrutide is the logical choice when the objective is maximal receptor coverage, because it already contains the GLP-1 activity that Ozempic provides plus the GIP and glucagon arms